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Available online 30 August 2016Objective: Qatar is a small country on the Eastern coast of the Arabian Peninsula. Its population is a unique
mixture of native citizens and immigrants. We aimed to describe the features of epilepsy in Qatar as such
information is virtually lacking from the current literature.
Methods:We summarized information retrospectively collected from 468 patients with epilepsy seen through
the national health system adult neurology clinic.
Results: Epilepsy was classiﬁed as focal in 65.5% of the cases and generalized in 23%. Common causes of
epilepsy were as follows: stroke (9%), hippocampal sclerosis (7%), infections (6%), and trauma (6%).
Sixty-six percent of patients were receiving a single antiepileptic drug, with levetiracetam being the most
frequently prescribed drug (41% of subjects). When the patients were divided by geographical background,
remote infections caused the epilepsy in 15% of Asian patients (with neurocysticercosis accounting for 10%)
but only in 1% of Qatari and 3% of Middle East/North African subjects (with no reported neurocysticercosis)
(p b 0.001). Cerebrovascular and neurodegenerative etiologies were the most prominent in Qataris,
accounting for 14% (p = 0.005) and 4% (p = 0.03) of cases, respectively. The choice of antiepileptic drugs
varied also according to the regional background, but the seizure freedom rate did not, averaging at 54%
on the last clinic visit.
Signiﬁcance: To our knowledge, this is the ﬁrst detailed information about epilepsy in Qatar. The geograph-
ical origin of patients adds to the heterogeneity of this disorder. Neurocysticercosis should be in the etiolog-
ical differential diagnosis of epilepsy in patients coming from Southeast Asian countries, despite the fact
that it is not endemic to Qatar. The choice of antiepileptic drugs is inﬂuenced by the availability of individual
agents in the patients’ native countries but had no bearing on the ﬁnal seizure outcome.





Epilepsy is one of the most prevalent neurologic conditions and
an important cause of disability and socioeconomic burden. It is ahe investigations were carried
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. This is an open access article underuniversal problem without national or ethnic boundaries, although
its prevalence and incidence vary between low- and high-income coun-
tries. Approximately 70million peopleworldwide suffer from the disor-
der; of which, 724,500 live in Arab countries [1–11]. Very little is known
about the epidemiology and other aspects of epilepsy in Qatar, a small
country located on the Northeastern coast of the Arabian Peninsula.
The country's population of just over two million represents a unique
mixture of native Qataris and a large number of expats; most of
whom are from other regions of the Middle East and North Africa
(MENA) and Asia (Qatar Statistics Authority). Studies describing the
characteristics of epilepsy in Qatar and in the larger Middle East or Ara-
bian Peninsula are rare [10,11] and do not address variables such as eti-
ology of epilepsy, treatment, or outcome. These features may be
inﬂuenced by the diversity within the same society, depending on so-
cioeconomic status as well as the different ethnic and national
backgrounds.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cross-sectional study, mining data on a sample of patients with epilepsy
(PWE) seen in a centralized national health system. The latter effectively
cares for almost all PWE in the country, providing a unique opportunity
for epidemiological studies on epilepsy.
2. Methods
2.1. Patients
This project involved a retrospective chart review of PWE followed in
the adult neurology clinic atHamadMedical Corporation (HMC), the state
health system that hosts the only comprehensive neurology services in
the country. The clinic provides care for subjects 14 years of age and
above. Almost all patients with epilepsy followed within Qatar receive
medical care at HMC. Thus, data from this single institute adequately rep-
resent the state of epilepsy in the country. Patients attending these clinics
between January 2014 and August 2014 had their charts reviewed after
approval by the Institutional Review Board. To be retained in the study,
patients must have had a clear diagnosis of epilepsy as deﬁned by the
ILAE [12]. They must have attended the clinic at least twice (to allow
outcome measurement and completion of the basic diagnostic workup).
Patients with a single seizure and relatively low risk of recurrence who
were left untreated and discharged, patients with provoked seizures, or
those with insufﬁcient medical information for diagnosis were excluded.
The patients' demographics (age, gender, nationality) were collected,
along with their employment status. We documented the age at onset
of epilepsy, pertinent personal and family history, seizure type(s), epilep-
sy syndrome, current and previous antiepileptic drugs (AEDs) used, neu-
roimaging and electroencephalographic ﬁndings, and presumed cause of
epilepsy and its severity (deﬁned according to seizure freedom versus re-
currence of seizures as reported at last visit). A family history for epilepsy
was obtained by scrutinizing the corresponding section in the clinic note
as documented from the initial clinic visit and referred to ﬁrst- and
second-degree relatives known to have epilepsy. All collected data were
entered in a speciﬁcally designed database and subsequently analyzed.
2.2. Statistical analysis
Demographic and clinical characteristics of patients were described
asmean and standard deviation for numerical variables and as frequen-
cy distribution for categorical variables. Patients were subsequently di-
vided according to their country of origin into three subgroups: Qatari,
from MENA region excluding Qatar, or Asian. Chi-squared test was
used to compare demographic and clinical variables between the
three groups. Patients from Europe, America, Australia, and South
Africa were excluded from the subgroup comparisons because of the
small sample size (n = 16). All analyses are carried out using IBM-
SPSS (version 23, Armonk, NY: IBM Corp, USA). A p-value of 0.05 or
less was considered statistically signiﬁcant.
Despite the inclusion of themost complete records, some individual
subjects still had missing information on one or more variables. We
quantiﬁed the missingness for such variables and found it to be less
than 3% for the epilepsy risk factors, etiology, imaging results, epilepsy
classiﬁcation, and outcome; at 5% for a detailed neurological exam; 6%
for employment; and 7% for EEG results. In order to obtain simpliﬁed
percentages that are useful for comparisonwith existing literature,we ex-
cluded the small amount of missing data from the calculated proportions
in the Results section.
3. Results
3.1. Demographics
The ﬁnal database contained 468 subjects. Two hundred eighty
(60%)weremen. Forty countries of originwere identiﬁed. One hundredeighty subjects (38%) are native Qataris, 118 (25%) were from other
MENA countries, and 154 (33%) were of Southeast Asian origin. Egypt
had the highest contribution to the MENA group with 24 patients,
whereas India and Nepal had the highest representation in the Asian
group with 63 and 30 patients, respectively. The mean age at ﬁrst sei-
zure was 25 (±17) and at last follow-up 34 (±15) years. Sixty percent
of subjects were employed or attending school regularly.
3.2. Risk factors
Six percent of patients had a history of perinatal/neonatal problems,
7% had a personal history of febrile seizures, 10% had a personal history
of mental retardation and/or cerebral palsy, and 16% had a family history
of seizures.
3.3. Seizure types and epilepsy syndromes
Generalized tonic–clonic seizureswere themost common seizure type,
noted in 89% of subjects. Focal seizures with impairment of consciousness
or awareness were seen in 19% of cases whereas focal seizures without
such impairment were observed in 22%. Myoclonus, absence, tonic, and
atonic seizures were noted in 11, 4, 2, and less than 1%, respectively.
Fifty-eight percent of subjects experienced only one type of seizure,
36% reported two types, and 6% had three or more types.
Epilepsywas classiﬁed as focal in 65.5%of cases (extratemporal in 29%,
temporal in 19%, and focalwithout further localization in 18%) and gener-
alized in 23% (juvenile myoclonic epilepsy (JME) in 10%, symptomatic
generalized in 5%, juvenile absence epilepsy in 2%). The remaining sub-
jects (11%) had no committed classiﬁcation as either focal or generalized.
3.4. Clinical and diagnostic features
Fifteen percent of patients had an abnormal neurological exam. Elec-
troencephalography was normal in 44.5% of subjects. It showed focal
epileptiform discharges in 32%, generalized epileptiform discharges in
17%, and nonspeciﬁc changes (e.g., focal or generalized slowing) in 6%.
Imaging with MRI and/or CT showed clear epileptogenic pathologies
in 40% and nonspeciﬁc changes (e.g., arachnoid cysts, cerebellar atro-
phy) in 3% and was normal in 57% of subjects.
3.5. Etiologies
Fifty-seven percent had no identiﬁable cause. Vascular causes,
including strokes and vascular malformations, were the most common
identiﬁed etiology, accounting for 11% of cases. The relevant etiologies
are shown in Fig. 1.
3.6. Treatment and outcome
Sixty-seven percent of patients were previously tried on at least one
AED other than the current treatment. Sixty-six percent of patientswere
currently on monotherapy, 24% were on two AEDs, and 9% were on
three or more. Overall, the most commonly prescribed drug was leveti-
racetam (41%) followed by valproic acid (25%), carbamazepine (22%),
and phenytoin (20%). On current therapy, 54% of patients were
seizure-free for at least six months. The remaining 46% with recurring
recent seizures included the 41% who showed a partial response
(more than 50% reduction in disabling seizure frequency between the
initial and last documented neurology clinic visits) and the 5% whose
seizures were refractory.
3.7. Epilepsy features by geographical background
Table 1 summarizes the relevant demographic and clinical variables
according to the region of origin. Some differences are highlighted in
this paragraph. More patients from an Asian background were male or
Fig. 1. “Structural/metabolic” etiologies of epilepsy. Vascular causes include strokes (9%)
and vascular malformations (2%). MCD: malformations of cortical development.
Table 1









Age at last follow up (years)
8–20 24 (13.3) 34 (28.8) 18 (11.7) b0.001⁎
21–40 92 (51.1) 55 (46.6) 93 (60.4)
41–60 38 (21.1) 25 (21.2) 40 (26.0)
60–82 26 (14.4) 4 (3.4) 3 (1.9)
Gender
Male 90 (50.0) 66 (55.9) 116 (75.8) b0.001⁎
Female 90 (50.0) 52 (44.1) 37 (24.2)
Employment
Yes 80 (47.3) 61 (54.5) 114 (77.6) b0.001⁎
No 89 (52.7) 51 (45.5) 33 (22.4)
Adverse neonatal/perinatal events
Present 16 (9.0) 6 (5.1) 7 (4.6) 0.210
Absent 162 (91.0) 111 (94.9) 146 (95.4)
Psychomotor delay/CP
Present 24 (13.6) 12 (10.3) 11 (7.2) 0.177
Absent 153 (86.4) 104 (89.7) 141 (92.8)
Febrile seizures
Yes 12 (6.8) 9 (7.8) 11 (7.2) 0.951
No 165 (93.2) 107 (92.2) 142 (92.8)
Family history of epilepsy
Present 36 (20.6) 18 (15.7) 19 (12.3) 0.128
Absent 139 (79.4) 97 (84.3) 135 (87.7)
Etiology
Unknown 95 (52.8) 70 (59.3) 86 (55.8) 0.536
Stroke 25 (13.9) 7 (5.9) 7 (4.5) 0.005⁎
Trauma 9 (5.0) 5 (4.2) 12 (7.8) 0.400
Neurodegeneration 7 (3.9) 2 (1.7) 0 (0.0) 0.030⁎
Tumors 4 (2.2) 0 (0.0) 5 (3.2) 0.134
Vascular malformation 5 (2.8) 3 (2.5) 0 (0.0) 0.084
MCDs 8 (4.4) 4 (3.4) 1 (0.6) 0.079
Hippocampal sclerosis 9 (5.0) 14 (11.9) 11 (7.1) 0.081
Infections 2 (1.1) 4 (3.4) 23 (14.9) b0.001⁎
(Neurocysticercosis) 0 (0.0) 0 (0.0) 15 (9.7) b0.001⁎
Other 7 (3.9) 10 (8.5) 8 (5.2) 0.232
Classiﬁcation
Partial 118 (67.0) 75 (64.1) 103 (66.9) 0.535
Generalized 40 (22.7) 33 (28.2) 32 (20.8)
Unclassiﬁed 18 (10.2) 9 (7.7) 19 (12.3)
Current AED
Valproate 48 (26.7) 33 (28.0) 35 (22.7) 0.572
Carbamazepine 44 (24.4) 21 (17.8) 32 (20.8) 0.380
Phenytoin 20 (11.1) 20 (16.9) 51 (33.1) b0.001⁎
Clonazepam 10 (5.6) 3 (2.5) 2 (1.3) 0.091
Clobazam 6 (3.3) 4 (3.4) 3 (1.9) 0.727
Lamotrigine 28 (15.6) 11 (9.3) 7 (4.5) 0.004⁎
Phenobarbital 2 (1.1) 1 (0.8) 4 (2.9) 0.449
Lacosamide 6 (3.3) 0 (0.0) 0 (0.0) 0.011⁎
Levetiracetam 89 (49.4) 55 (46.6) 43 (27.9) b0.001⁎
Topiramate 22 (12.2) 12 (10.2) 2 (1.3) 0.001⁎
Oxcarbazepine 12 (6.7) 1 (0.8) 8 (5.2) 0.061
Response
Seizure-free 85 (47.8) 67 (57.3) 90 (59.2) 0.101
Partial 80 (44.9) 47 (40.2) 57 (37.5)
Refractory 13 (7.3) 3 (2.6) 5 (3.3)
MENA: Middle East and North Africa. CP: cerebral palsy. AED: antiepileptic drug. MCD:
malformation of cortical development.
⁎ Signiﬁcant difference at the 5% level.
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patients were 60 years of age or older (14%) compared with MENA or
Asian patients (3 and 2%, respectively).
The incidence of a positive family history for epilepsy ranged from
12% in Asians to 21% in Qataris, a difference that reached statistical sig-
niﬁcance (p= 0.04) when these two groups were compared excluding
the MENA patients who had an intermediate family history rate of 16%.
Overall, strokes accounted for 9% of epilepsy cases. Subgroup analy-
sis showed that strokes contributed to 14% of cases in Qataris but less
than 6% in MENA and Asian patients (p = 0.005). Neurodegenerative
disorders, including mainly dementias of various types, accounted for
2% of epilepsy cases overall. They contributed to 4% of cases among
Qataris but only 2% of MENA patients and none in the Asian subgroup
(p=0.03). Remote infections accounted for 6% of epilepsy cases overall,
with 15% of cases in Asians but only 1 and 3% among Qatari and MENA
subjects, respectively (p b 0.001). Neurocysticercosis (NCC) accounted
for more than half of the infections seen in Asians (10% of our Asian
PWE) but was absent in the other subgroups (p b 0.001).
Furthermore, on additional scrutiny of the speciﬁc countries of origin
for the 15 individuals with NCC, 12 came from Nepal. This represented
40% of our PWE from this single country. The remaining three patients
with NCC were from India and the Philippines.
The most commonly prescribed drug among Qatari and MENA
patients was levetiracetam (49 and 47%, respectively) while phenytoin
was the most prescribed drug in patients of Asian origin (33%). Despite
the difference in treatment choices, the seizure outcome did not vary
between the subgroups. The seizure-free rate reached 48% in Qataris,
57% in MENA subjects, and 59% in Asians (p = 0.1).
4. Discussion and conclusion
Little is known about the epidemiology or other aspects of epilepsy
in Qatar, a small country with a rich mix of ethnic backgrounds. We
found only one published study on the topic of epilepsy in this country
[13]. Based on data collected between 1992 and 2000, that study
postulated an annual incidence of epilepsy in Qatar of 174 per 100,000
persons, a ﬁgure considerably higher than that reported in most other
regions [10]. The authors did not detail the patients' characteristicsand did not specifywhether single and provoked seizureswere included.
In addition, the population of the country has quadrupled since.
In our cohort, GTC seizures were by far the most common seizure
type, with epilepsy diagnosed as focal in the majority of subjects. Al-
though there are inconsistencies in the international literature about
the proportion of the different seizure types and epilepsy syndromes,
most published studies suggest a larger contribution of focal epilepsy
to the burden of disease, particularly in adults [6,8,14–20]. Focal epilep-
sy wasmore often extratemporal than temporal in our population. This
differentiationwas based on the clinicalmanifestations at seizure onset,
101N. Haddad et al. / Epilepsy & Behavior 63 (2016) 98–102as well as the EEG and neuroimaging data. Manford et al. reported sim-
ilar ﬁndings from the United Kingdom; among 160 patients with focal
epilepsy and a localizable seizure onset, more than 60% were attributed
to extratemporal foci [21]. In our present series, among the generalized
epilepsy syndromes, JME was the most common single entity, account-
ing for 10% of our cohort. In a study from Saudi Arabia, Obeid and
Panayiotopoulos reported a strikingly similar proportion of 10.7%
(42 out of 391 cases) from an adult epilepsy clinic (age over 15 years)
[22]. The prevalence of JME in large cohorts varies between studies
and has been estimated to be ﬁve to 10% of all epilepsies. As the seizures
of most patients with this syndrome are easily controlled, lower
prevalence is reported in highly specialized clinics because of referral
bias, whereas less selective clinics like ours tend to report the higher
proportion [23,24].
The revised ILAE classiﬁcation recommended abandoning terms
such as idiopathic, symptomatic, and cryptogenic when describing the
underlying cause [25]. Accordingly, the etiology of epilepsy was pre-
sumed genetic or unknown in 57% of our cases, a proportion that falls
within the previously published range for epilepsy with unidentiﬁed
causes [6,15,17–20]. The rest of our patients had an identiﬁable etiology
(structural/metabolic), with stroke, trauma, infections, and hippocampal
sclerosis leading in this category.
Most AEDs are available in Qatar, and their cost is, in part, subsidized
by the state. Levetiracetam is the most commonly prescribed AED in
Qatar. This treatment trend is likely explained by the drug's broad
efﬁcacy across many seizure types, ease of dose escalation, favorable
side effect proﬁle, and reduced drug interactions [26,27]. Not surprisingly,
themore traditional AEDs (e.g., valproate, carbamazepine, phenytoin) are
also commonly used.
Of particular interest are the differences we found between our pa-
tients based on their native region. Abou-Khalil et al. systematically
questioned patients about family history of epilepsy and reported that
32.8% of the studied patients in the Vanderbilt Epilepsy Program in
Tennessee had a positive family history (ﬁrst- or second-degree
relatives) of epilepsy [28]. The family history may be underreported in
a retrospective study like ours, but the difference between the
subgroups is worth noting. A positive family history of epilepsy was
more common in our native Qatari subgroup at a rate of 21%, compared
with that in 12% in our Asian patients. This ﬁndingmay suggest a stron-
ger genetic predisposition in the Qatari nationals and could be at least
partially explained by the high prevalence of parental consanguinity.
Consanguineous unions account for more than 50% of marriages in the
State of Qatar [11,29], a factor that is reported to increase the risk of
epilepsy in the offspring (genetic/idiopathic epilepsy in particular)
[4,9,30]. Similarly, elevated rates of family history are also reported in
PWE from neighboring Saudi Arabia [31].
The contributing etiology varied with geographical background.
Remote infections, especially NCC, were the most commonly identiﬁed
cause of epilepsy in our Asian subgroup. This is consistentwith the liter-
ature suggesting a high contribution of infections to epilepsy cases in
developing countries in general and the speciﬁc high rate of NCC in
Southeast Asia, Latin America, and sub-Saharan Africa [4,7,8,16,31].
Nearly one-third of epilepsy cases were associated with NCC in both
urban and rural areas of Vellore, India [32]. Among 300 incident cases
of epilepsy in Nepal, 47% were caused by NCC [33]. This is comparable
with our 40% rate of NCC in immigrant PWE from Nepal, the country
with the highest NCC contribution in our database. The rate of remote
infections in the Qatari and MENA subjects was lower and comparable
with what is reported in cohorts with epilepsy from Europe and North
America [19,20]. No NCC cases were identiﬁed in these subgroups in
our study. Stroke is the most frequently identiﬁed cause of epilepsy in
industrialized countries, accounting for nine to 18% of all new cases
and about one-third of cases with an identiﬁed cause [6,15,19,20]. Our
native Qatari group parallels this ﬁnding. As the etiology of epilepsy is
age-dependent [18], it is not surprising that cerebrovascular disease
was an important contributor to the burden of epilepsy in our Qataripatients, who represented the bulk of our subjects over 60. The same
applies to neurodegenerative disorders.
The treatments utilized also differed, with the Qatari and MENA
subjects being more likely to receive the newer AEDs. This practice
could be understood through a ﬁnancial and socioeconomic scope. Al-
though most AEDs are available and subsidized by the state, the co-
pay for the newer drugs is much higher. Many of our Asian patients
are laborers on a limited income, leading to being more mindful about
the cost incurred by the patient in this speciﬁc population. Also, since
anticonvulsant treatment is typically chronic, the availability and af-
fordability of the prescribed drug once the patient relocates to his native
country need to be taken into account (expats are on speciﬁed term
contracts). Old AEDs are globally available, whereas newer ones are
less widely marketed in some Asian and developing countries, in addi-
tion to their prohibitive cost [4,7,8,31,33–37]. Despite the difference in
treatment choices, the seizure outcome did not vary signiﬁcantly be-
tween the subgroups. The rate of seizure freedom at the last follow-up
was 54%. This proportion is hard to comparewith published data on sei-
zure remission because of major methodological differences; long-term
remission is achieved in 60–85% in most published longitudinal cohort
studies [38–41]. Our population is likely skewed towards patients
with active epilepsy requiring regular clinic visits and who have a
higher chance of being captured in this time-limited data collection
period.
Our study has certain limitations because of its retrospective nature
and the lack of a longitudinal follow-up to better characterize the out-
come. The family history is particularly difﬁcult to accurately quantify
in a retrospective study, with a high risk of underreporting.
With the paucity of reliable sources describing the state of epilepsy
in Qatar, we believe that our study is a major step to that end. In fact,
because of similarities in population composition with neighboring
countries, our study may be representative of the characteristics of epi-
lepsy and its management in thewhole Arabian Peninsula. Furthermore,
despite the relatively small size of the country's population and the sin-
gle health system source of the data, the rich mix of subjects of varied
geographical backgrounds and socioeconomic states leads to signiﬁcant
heterogeneity in some epilepsy features, most notably regarding causes
of epilepsy and treatment trends. Our population showedmixed features
reported from both industrialized and developing countries, a trend that
may becomemore commonwith population shifts and increasing immi-
gration. Despite the fact that NCC is not endemic to Qatar, it has to be in
the etiological differential diagnosis of PWE residing in Qatar but origi-
nating from countries in Southeast Asia, especially Nepal.
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